Citius Pharmaceuticals, Inc. (CTXR) stock
CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.53−0.01 (-1.40%)
Close on Nov 16, 2026Market cap $14.48MP/E –Yield –
Citius Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Citius Pharmaceuticals's total assets was $142.26M at Jun 30, 2026. For fiscal 2025 it was $130.94M, up 12.2% from the year before. Over ten years it grew 296.9% a year on average. The highest annual figure on record is $142.43M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $130.94M | +12.2% |
| FY2024 | Sep 30, 2024 | $116.65M | +12.6% |
| FY2023 | Sep 30, 2023 | $103.61M | -9.1% |
| FY2022 | Sep 30, 2022 | $114.00M | -20.0% |
| FY2021 | Sep 30, 2021 | $142.43M | +225.4% |
| FY2020 | Sep 30, 2020 | $43.77M | +19.1% |
| FY2019 | Sep 30, 2019 | $36.75M | +18.3% |
| FY2018 | Sep 30, 2018 | $31.05M | +27.2% |
| FY2017 | Sep 30, 2017 | $24.42M | +11.2% |
| FY2016 | Sep 30, 2016 | $21.95M | +16259411.9% |
| FY2012 | Sep 30, 2012 | $135 | -36.3% |
| FY2011 | Sep 30, 2011 | $212 | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $142.26M | +11.4% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $132.54M | +9.1% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $140.39M | +16.3% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $130.94M | +12.2% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $127.68M | +31.5% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $121.48M | +33.9% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $120.70M | +23.9% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $116.65M | +12.6% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $97.09M | -12.1% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $90.71M | -18.8% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $97.40M | -14.6% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $103.61M | -13.9% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $110.40M | -13.6% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $111.71M | -18.8% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $114.00M | -20.0% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $120.32M | -17.9% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $127.79M | -5.1% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $137.52M | +289.4% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $142.43M | +225.4% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $146.59M | +281.8% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $134.67M | +408.3% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $35.31M | +41.3% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $43.77M | +19.1% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $38.40M | +50.3% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $26.49M | +9.3% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $24.98M | -11.0% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $36.75M | +18.3% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $25.54M | +7.2% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $24.24M | -7.0% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $28.08M | -1.4% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $31.05M | +27.2% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $23.83M | +10.5% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $26.06M | +22.2% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $28.47M | +32.5% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $24.42M | +11.2% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $21.57M | -6.3% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $21.33M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $21.48M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $21.95M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $23.01M | – |
See a number that looks wrong?